Study Summary
This trial is testing a new drug for safety and how well it works in patients with cancer who have already tried other treatments.
- Solid Tumors
- Primary Peritoneal Carcinoma
- Small Cell Lung Cancer
- Microsatellite Instability-High Cancer
- Clear Cell Renal Cell Carcinoma
- Ovarian Cancer
- High Tumor Mutational Burden Cancer
- Neuroendocrine Tumors
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
9 Primary · 30 Secondary · Reporting Duration: Up to 5 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
Part A
1 of 2
Part B
1 of 2
Experimental Treatment
140 Total Participants · 2 Treatment Groups
Primary Treatment: 23ME-00610 · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age Any Age · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
Michigan | 100.0% |
What site did they apply to?
Karmanos Cancer Institute | 100.0% |
What portion of applicants met pre-screening criteria?
Did not meet criteria | 100.0% |
Why did patients apply to this trial?
- "I'm getting treatment with Keytruda every three weeks. I have endometrial cancer mets to my abdomen and pelvic area, stage4."
Frequently Asked Questions
Are there any vacancies for participants in this research endeavor?
"According to information hosted on clinicaltrials.gov, this medical experiment is actively recruiting patients and has been since it was first posted in December 2021 with the most recent update coming November 2022." - Anonymous Online Contributor
Could you kindly provide the overall count of participants involved in this clinical trial?
"To fulfill the requirements of this medical experiment, 105 people who meet all necessary selection criteria are needed. Patients can be recruited from Princess Margaret Cancer Centre in Toronto, Texas and Oregon's Investigational Site located in San Antonio." - Anonymous Online Contributor
What potential hazards can be associated with 23ME-00610?
"Due to the limited data regarding 23ME-00610's efficacy and safety, our team at Power rated it a 1 on its scale of 1 to 3." - Anonymous Online Contributor
Are there numerous sites in the U.S. conducting this medical trial?
"This study is currently being conducted in 6 different sites, including Toronto, San Antonio and Houston. To reduce travel demands if you decide to take part, it's recommended that you choose the closest location near you." - Anonymous Online Contributor